Drug Discovery - Research & Development

Haisco and Nuvectis sign licensing deal for two drugs

Haisco Pharmaceutical Group has signed an exclusive licensing agreement granting US-based biotechnology company Nuvectis rights for two drug candidates in oncology and complement indications.

Genprex’s Reqorsa combo secures Canadian patent for lung cancer

Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the use of its Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either programmed cell death protein 1 (PD-1) or PD-L1 antibodies to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Lilly and BioArctic sign deal to develop neurodegenerative therapy

Eli Lilly and Company has signed a research and collaboration agreement with Swedish biopharmaceutical company BioArctic to develop a potential treatment for neurodegenerative diseases.

Sun Pharma to acquire Innovcare Lifesciences for $28.7m

Sun Pharmaceutical Industries has agreed to purchase India-based Innovcare Lifesciences in a deal valued at approximately Rs2.71bn ($28.7m).

Voro and Alloy partner on tumour-selective TCE therapeutics

Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.

Biogen to acquire RayThera for up to $1bn

Biogen has entered a definitive agreement to acquire RayThera, a biotechnology company specialising in small-molecule therapies for immunology, for up to $1bn.

Jazz and AbCellera sign deal for T-cell engagers in solid tumours

Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of T-cell-engaging multispecific antibodies, or T-cell engagers (TCEs), for gastrointestinal (GI) cancers and other solid tumours.

LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs

LG AI Research and D&D Pharmatech have entered an agreement to collaborate on the development of next-generation oral peptide drugs, the companies announced following a signing ceremony held at the LG Twin Towers in Yeouido, Seoul, South Korea.

AviadoBio broadens vMiX gene silencing licence with King’s College London

AviadoBio has extended its exclusive licence agreement with King’s College London to apply the vMiX ribonucleic acid interference (RNAi) gene-silencing platform across all human therapeutic areas.